ProTherm, the thermodynamic database for proteins and mutants, is the largest source of thermodynamic protein stability data, containing over 25,000 entries. Although the ProTherm website is no longer being supported, we are providing continued access to this valuable resource by incorporating the ProTherm data into ProtaBank. All the entries have been converted to the ProtaBank study format using automated scripts. For the raw ProTherm data, access to these scripts, or more information, check out our github at https://github.com/protabit/protherm-conversion.
A paper describing ProtaBank, our online protein engineering database, has been accepted for publication and will be featured in the upcoming issue of Protein Science. Check it out:
Visit ProtaBank online at: protabank.org
The National Institutes of Health awarded Protabit a Phase II SBIR grant to continue development of their protein engineering database. The database will provide a central repository for all types of protein engineering data spanning a wide range of protein properties. The design features a standard format for reporting mutant protein sequences and experimental assay data that will facilitate comparison of results across different data sets. A suite of analysis and visualization tools will be provided to support discovery and guide future designs. Having large amounts of protein mutant data in an organized, searchable database is expected to facilitate machine learning and data mining, help scientists gain insights into sequence-function relationships, and support the development of new predictive tools and algorithms.
More on this award can be found at SBIR.gov.
The National Institutes of Health awarded Protabit a Fast-Track SBIR grant to develop a database for protein engineering (PE) data. The database will provide a comprehensive central repository for all types of protein engineering data spanning a wide range of protein properties. It aims to provide an industry-wide standard format for PE data and a suite of analysis and visualization tools to support discovery and guide protein design. The database will help facilitate machine learning and data mining approaches to protein engineering, support the development of new predictive tools and algorithms, and help scientists gain insights into sequence-function relationships.
More on this award can be found at SBIR.gov.
The National Institutes of Health (NIH) has awarded a Phase II Small Business Innovation Research (SBIR) grant to Protabit to continue development of Triad, their web-based software for computational protein design and engineering. By combining automated workflows, interactive analysis and visualization tools, and the convenience of cloud computing, this NIH support will allow Protabit to further their goals in making cutting edge protein engineering software easy to use and accessible to bench scientists.
This NSF Phase II STTR award will allow Protabit to develop a computational protein engineering (CPE) "platform technology" that enables new products and techniques in a wide range of scientific areas, including industrial enzymes, pharmaceuticals, therapeutics, medical diagnostics, and bioenergy. In collaboration with the Mayo lab at Caltech and the Rosenzweig lab at Northwestern University, Protabit will build on its Phase I efforts and validate the CPE platform by engineering a solubly-expressed methane monooxygenase (MMO) with improved methane-oxidizing activity. An additional goal is to work with potential licensees of this technology to incorporate the engineered enzyme into their industrial host organisms, thereby allowing them to use methane as a feedstock for the bio-production of a wide range of end products, including liquid transportation fuels, commodity chemicals, and high value fine chemicals.
More on this award can be found at SBIR.gov.
Protabit is preparing to release TriadWeb, a web-based, protein design service built upon Protabit’s Triad software platform and utilizing the Amazon Elastic Compute Cloud. This service is designed to be simple, secure, user-friendly, and reliable, making it easy for bench scientists to execute protein designs and translate them into protein variant libraries that are easy to construct and express in the laboratory.
For now, TriadWeb is available for trial and subscription by
invitation only. If you’re interested in learning more about TriadWeb
and being included in the next group of trial customers, please submit
your name, organization, and email in our contact form at the bottom of the page.
PASADENA, CA (PRWEB), February 04, 2015 — The National Institutes of Health (NIH) has awarded a grant to Protabit LLC to make its commercial-grade computational protein design (CPD) software platform, Triad, available to subscribers as a new software-as-a-service.
Engineered proteins are used as antibody-based human therapeutics, in microbial pathways for the production of bio-based fuels and chemicals, and in numerous other applications. Current engineering methods rely heavily on large-scale screening in the laboratory. Triad speeds the discovery of new or enhanced proteins by using computer modeling to focus screening efforts on amino acid sequences that are most likely to be useful. The core technology for Triad was developed over the past 5 years in partnership with Monsanto and the laboratory of Stephen Mayo at the California Institute of Technology, and it features cutting edge protein design, modeling, and analysis tools.
Current CPD platforms are powerful but complicated and difficult to use, and they require costly computer systems to execute the intensive calculations required for protein design. The objective of the NIH Small Business Innovation Research (SBIR) Phase I project is to make CPD broadly accessible by harnessing the power and convenience of cloud computing. Protabit is developing Triad into a web-based, easy-to-use, collaborative CPD software application that is available by subscription, without the hassle of installing software or purchasing and maintaining expensive hardware. Triad will feature user authentication and encryption, secure data sharing, and interactive visualization tools.
Dr. Barry Olafson, Protabit CEO and co-founder, is the principal investigator on the NIH project. “We are pleased to receive this grant from NIH, which will allow us to make our powerful Triad software platform widely available via the cloud. Monoclonal antibodies and other protein therapeutics have broad applications in the treatment of cancer and other diseases. Through Triad, we aim to facilitate engineering these valuable proteins for new and improved properties.”
Dr. Amos Anderson is the lead software architect for the Triad web
platform. “Triad is built for the bench scientist. We’re making our
substantial protein engineering expertise accessible to others through
automated workflows and focused, visual output, making it easy to
analyze and design proteins.”
Marni Usheroff from the Los Angeles Business Journal has written a news article about Protabit and Triad, our computational protein design software: http://labusinessjournal.com/news/2015/jan/26/protein-engineer-sees-software-building-block/
A PDF of the article is available here: LABJ_Protabit_article.
Protabit has been awarded a DOE Phase I Small Business Technology Transfer (STTR) grant to engineer a more efficient dihydroxyacid dehydratase, a key bottleneck enzyme in the biosynthesis of isobutanol from glucose. Protabit is partnering with the California Institute of Technology on this 9-month Phase I effort. The team will apply computational protein design to engineer a cofactor swap, substituting a simple Mg2+ cofactor in place of a complicated, energetically expensive cofactor (Fe-S cluster).
More on this award can be found at SBIR.gov: https://www.sbir.gov/sbirsearch/detail/687660.
ARPA-E has awarded a $1 million grant to a team of scientists and enzyme engineers at Northwestern University, the California Institute of Technology, and Protabit LLC to engineer more efficient methane activating enzymes. The team is led by Prof. Amy C. Rosenzweig of Northwestern and includes the laboratories of Prof. Michael Jewett at Northwestern and Prof. Stephen Mayo at Caltech. Protabit is providing the computational protein design software and engineering expertise.
The objective of the 1-year effort is to develop efficient and versatile enzymes that can chemically activate methane, enabling the biosynthesis of liquid fuels and chemicals from natural gas. ARPA-E is providing funding for the effort via its Reducing Emissions using Methanotrophic Organisms for Transportation Energy (REMOTE) program.
PASADENA, CA, February 6, 2014 — The National Science Foundation (NSF) awarded a Small Business Technology Transfer (STTR) Phase I grant to an industry-academic partnership led by Protabit LLC. In collaboration with the Mayo lab at the California Institute of Technology and the Rosenzweig lab at Northwestern University, Protabit will engineer enzymes that convert methane to methanol as part of a biosynthetic pathway that uses natural gas to produce fuels and high-value chemicals.
The project focuses on creating a soluble, active methane monooxygenase (MMO) that expresses well in a recombinant host and is amenable to high-throughput protein engineering. Dr. Amy Rosenzweig, professor in the Department of Molecular Biosciences and the Department of Chemistry at Northwestern and a leading authority on MMOs, noted, “Unlike chemical catalysts, MMOs can selectively oxidize methane under ambient conditions and may thus provide a useful model for an efficient, environmentally sound catalyst.”
Protabit will apply its computational protein design software to engineer improved MMOs. “Use of Protabit’s state-of-the-art computational tools will allow us to generate and screen libraries of novel sequences to rapidly identify recombinant MMO variants with the desired properties,” said Dr. Stephen Mayo, Protabit co-founder and Chair of the Division of Biology and Biological Engineering at Caltech.
Dr. Barry Olafson, Protabit CEO and co-founder added, “We are pleased to receive this grant from the NSF, which will allow us to develop a platform for optimizing an MMO for industrial use. An optimized MMO is key for the biosynthetic conversion of methane gas to biofuels and chemicals. This process can then be incorporated into a modular micro-scale gas-to-liquids solution that can reduce or eliminate wasteful gas flaring at remote gas sources. We remain committed to improving and applying our software to help develop solutions to reduce our nation’s dependence on foreign oil and decrease our carbon footprint.”
PASADENA, CA (PRWeb), July 1, 2013 — The National Science Foundation awarded a Small Business Technology Transfer (STTR) Phase I grant to Protabit LLC, a Pasadena-based spin-out from the California Institute of Technology. The grant will be used to engineer cellulase-enhancing enzymes called polysaccharide monooxygenases (PMOs) for the production of biofuels from non-edible corn stover biomass. The abstract of the grant is available here: http://nsf.gov/awardsearch/showAward?AWD_ID=1332185.
At the core of Protabit’s engineering approach is Triad, a computational protein design software platform that is used to generate new enzymes for experimental evaluation. Triad is the product of research by thought leaders in the field including Prof. Stephen Mayo, chair of the Division of Biology and Biological Engineering at Caltech and a co-founder of the company. For this STTR project, Protabit will apply Triad to generate libraries of possible enzyme variants predicted to be stable at higher temperatures; the team at Caltech will then produce these enzymes and screen them for the desired properties using robotics-enabled high-throughput techniques.
“This grant from the NSF may help reduce America’s dependence on foreign oil by enabling Protabit to develop more efficient cellulases for advanced biofuels,” said Dr. Barry Olafson, CEO and co-founder. “Because they are derived from non-edible biomass, these biofuels can also reduce our carbon footprint without impacting the global food supply.”
PASADENA, CA (PRWeb), June 28, 2012 — The National Science Foundation awarded a Small Business Innovative Research (SBIR) Phase I grant to Protabit LLC, a Pasadena-based spin-out from the California Institute of Technology. The grant will be used to engineer cellulase enzymes for the production of biofuels from non-edible corn stover biomass.
Protabit is the developer of Triad, a computational protein design software platform that is used to generate new enzymes for experimental evaluation. Triad is the product of research by thought leaders in the field including Prof. Stephen Mayo, chair of the Division of Biology at Caltech and a co-founder of the company.
Dr. Barry Olafson, CEO and Co-Founder said, “We are pleased to receive this grant from the NSF, which will enable Protabit to accelerate its development of novel cellulases for second generation biofuels. Triad’s computational capabilities will provide a rich source of high-performance enzyme sequences for evaluation and testing. Our research seeks to help reduce America’s dependence on foreign oil without impacting the global food supply.”
ST. LOUIS and PASADENA, CA., June 11, 2009 — Monsanto Company (NYSE: MON) and Pasadena-based Protabit LLC, today announced a two-year collaboration to develop new tools for protein design and optimization.
All organisms produce a diverse set of proteins to express characteristic attributes, which in plants can include tolerance to drought and pests. Monsanto agricultural biotechnology researchers use high-throughput protein design and optimization technologies to rapidly design more effective proteins to confer beneficial traits in crops.
Development of improved software tools for protein design and optimization can help shorten the product discovery process. This would enable Monsanto to more quickly identify pipeline gene candidates in support of the company’s sustainability goal of doubling yields in its core crops of corn, cotton, and soybeans by 2030, compared to a base year of 2000.
“We believe that utilizing state-of-the-art protein design software, coupled with our high-throughput gene synthesis and protein purification platforms, will further strengthen our R&D pipeline and maintain Monsanto’s leadership in the field of biotech crops,” said Steve Padgette, vice president of biotechnology for Monsanto. “The partnership with Protabit will help Monsanto stay on the leading edge of innovation and ensure that farmers continue to have access to valuable traits as quickly as possible, so that they can continue to boost on-farm productivity. We are excited by the opportunity to work closely with the Protabit team to accelerate our unique approach to high-throughput protein design pioneered by our research teams in Cambridge, Massachusetts and St. Louis.”
Protabit is a start-up company founded by Stephen Mayo, PhD, of the California Institute of Technology. Dr. Mayo is a leader in the field of computational protein design and expects the software created by Protabit to have broad applicability as a protein improvement and discovery tool in biotechnology.
“Recent advances in protein sequence design coupled to robotic expression of proteins will dramatically improve the efficacy of computational protein design methodology,” Mayo said. “We look forward to collaborating with Monsanto on both the development of new methodology and its application to protein design projects that lead to new and/or improved products in the ag biotech arena.”